AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30285823 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based education program
Number of subjects: 1820
Study 30285823 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1820
Study 27707148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1 (10-month leadership development program)
Number of subjects: 177
Study 27707148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2 (10-month leadership development program)
Number of subjects: 177
Study 27707148 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of both interventions
Number of subjects: 177
Study 24625200 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin (1 million IU, n = 73)
Number of subjects: 144
Study 24625200 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.45% saline, n = 71)
Number of subjects: 144
Study 24625200 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin (1 million IU, n = 73) in adherent patients (adherence quartiles 2-4)
Number of subjects: 144
Study 24625200 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.45% saline, n = 71) in adherent patients (adherence quartiles 2-4)
Number of subjects: 144
Study 22157519 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan 40 mg per day
Number of subjects: 430
Study 22157519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 430
Study 20023047 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg daily
Number of subjects: 0
Study 18000167 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-drug induction combination (including idarubicin, fludarabine, interleukin-2)
Number of subjects: 901
Study 18000167 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-drug reinduction
Number of subjects: 901
Study 18000167 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine/cytarabine/idarubicin
Number of subjects: 901
Study 18000167 — intervention group
Group type: COMPARATOR
Intervention: Interleukin-2
Number of subjects: 901
Study 18000167 — intervention group
Group type: COMPARATOR
Intervention: Related donor availability
Number of subjects: 901
Study 18000167 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 901
Study 18000167 — intervention group
Group type: COMPARATOR
Intervention: Time period 1996-1998
Number of subjects: 901
Study 18000167 — intervention group
Group type: COMPARATOR
Intervention: Time period 2000-2002
Number of subjects: 901
Study 18000167 — intervention group
Group type: COMPARATOR
Intervention: Treatment-related mortality
Number of subjects: 901
Study 15738453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low target blood pressure (mean arterial pressure < 92 mm Hg)
Number of subjects: 840
Study 15738453 — intervention group
Group type: COMPARATOR
Intervention: Usual target blood pressure (mean arterial pressure < 107 mm Hg)
Number of subjects: 840
Study 12533152 — intervention group
Group type: EXPERIMENTAL
Intervention: AlloDerm graft (group 1)
Number of subjects: 30
Study 12533152 — intervention group
Group type: COMPARATOR
Intervention: No interpositional barrier (group 2)
Number of subjects: 30
Study 12533152 — intervention group
Group type: COMPARATOR
Intervention: Deep-plane rhytidectomy (group 3)
Number of subjects: 30
Study 10450813 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond-coated sonic scaler inserts
Number of subjects: 15
Study 10450813 — intervention group
Group type: COMPARATOR
Intervention: Hand instruments
Number of subjects: 15
Study 8705151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 40
Study 8705151 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 40
Study 2368857 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation after one year
Number of subjects: 12866
Study 2368857 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation for at least three years
Number of subjects: 12866
Study 2368857 — intervention group
Group type: COMPARATOR
Intervention: Smoking (current smokers)
Number of subjects: 12866
Study 2368857 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation (quitters)
Number of subjects: 12866
Study 98128 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg protirelin per day for 14 days
Number of subjects: 143
Study 98128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 29255885 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral low-frequency (20 Hz) NBM DBS
Number of subjects: 6
Study 29255885 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 6
Study 29255885 — intervention group
Group type: COMPARATOR
Intervention: Preoperative baseline
Number of subjects: 6
Study 27036394 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin (ERN) plus simvastatin/ezetimibe
Number of subjects: 3414
Study 27036394 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin/ezetimibe plus placebo
Number of subjects: 3414
Study 25271149 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture
Number of subjects: 150
Study 25271149 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal acupuncture
Number of subjects: 150
Study 25271149 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive sham acupuncture
Number of subjects: 150
Study 22865313 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial catheterization (TRI)
Number of subjects: 119
Study 22865313 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral catheterization (TFI)
Number of subjects: 119
Study 20538217 — intervention group
Group type: EXPERIMENTAL
Intervention: Greek traditional dances (1 hour)
Number of subjects: 111
Study 20538217 — intervention group
Group type: COMPARATOR
Intervention: Control group (discussion and watching television for 1 hour)
Number of subjects: 111
Study 18503578 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated approach of yoga therapy (IAYT)
Number of subjects: 108
Study 18503578 — intervention group
Group type: COMPARATOR
Intervention: Control group (simple physical exercises)
Number of subjects: 108
Study 15649828 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glycoalkaloid (TGA) doses of 0.30 mg/kg BW
Number of subjects: 6
Study 15649828 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glycoalkaloid (TGA) doses of 0.50 mg/kg BW
Number of subjects: 6
Study 15649828 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glycoalkaloid (TGA) doses of 0.70 mg/kg BW
Number of subjects: 6
Study 15649828 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potatoes with TGA doses of 0.95 mg/kg BW
Number of subjects: 6
Study 15649828 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potatoes with TGA doses of 1.10 mg/kg BW
Number of subjects: 6
Study 15649828 — intervention group
Group type: EXPERIMENTAL
Intervention: Mashed potatoes with TGA doses of 1.25 mg/kg BW
Number of subjects: 6
Study 12678198 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) plus dexrazoxane (DEX) (60 mg, daily dose)
Number of subjects: 61
Study 12678198 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) only
Number of subjects: 61
Study 12678198 — intervention group
Group type: COMPARATOR
Intervention: Dexrazoxane (DEX) only
Number of subjects: 61
Study 10526899 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smoke exposure (carbon monoxide concentration between 20 and 40 p.p.m.)
Number of subjects: 12
Study 10526899 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (room air)
Number of subjects: 12
Study 10526899 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion
Number of subjects: 12
Study 10526899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP) infusion
Number of subjects: 12
Study 7721406 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg BID)
Number of subjects: 6
Study 7721406 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (60 mg OD)
Number of subjects: 6
Study 2259927 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tamoxifen citrate 10 mg twice daily
Number of subjects: 156
Study 2259927 — intervention group
Group type: COMPARATOR
Intervention: Oral megestrol acetate 40 mg four times a day
Number of subjects: 156
Study 7402688 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine infusion at 0.16, 0.33, and 0.66 microgram/kg/min
Number of subjects: 48
Study 7402688 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine infusion
Number of subjects: 48
Study 7402688 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 blocking agent (mepyramine)
Number of subjects: 48
Study 7402688 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 blocker (cimetidine)
Number of subjects: 48
Study 7402688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 6389385 — intervention group
Group type: EXPERIMENTAL
Intervention: Alclometasone dipropionate cream 0.05%
Number of subjects: 43
Study 6389385 — intervention group
Group type: COMPARATOR
Intervention: Clobetasone butyrate cream 0.05%
Number of subjects: 43
Study 31305275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive nephrectomy followed by sunitinib
Number of subjects: 0
Study 31305275 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib alone
Number of subjects: 0
Study 31305275 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial sunitinib followed by deferred cytoreductive nephrectomy
Number of subjects: 0
Study 29453980 — intervention group
Group type: EXPERIMENTAL
Intervention: RFVE with CR
Number of subjects: 136
Study 29453980 — intervention group
Group type: COMPARATOR
Intervention: CR
Number of subjects: 136
Study 27015295 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 210
Study 27015295 — intervention group
Group type: COMPARATOR
Intervention: Conventional combination treatment (sulfasalazine plus hydroxychloroquine)
Number of subjects: 210
Study 25062129 — intervention group
Group type: EXPERIMENTAL
Intervention: balafilcon A (silicone hydrogel)
Number of subjects: 108
Study 25062129 — intervention group
Group type: COMPARATOR
Intervention: etafilcon A (hydrogel)
Number of subjects: 108
Study 22378918 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (target blood level 0.4‐0.8 mEq/l)
Number of subjects: 133
Study 22378918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 22378918 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 133
Study 22378918 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate and Placebo
Number of subjects: 133
Study 20631694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg intravenously)
Number of subjects: 12
Study 20631694 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone (50 microg orally)
Number of subjects: 12
Study 20631694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone and Fludrocortisone (combined)
Number of subjects: 12
Study 20631694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17016794 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine treatment for OAB over 12 weeks
Number of subjects: 1211
Study 15661432 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (5‐HT3‐antagonist)
Number of subjects: 20
Study 15661432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15661432 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac‐sodium (PGE2‐antagonist)
Number of subjects: 20
Study 12182264 — intervention group
Group type: COMPARATOR
Intervention: Health information intervention (I only)
Number of subjects: 161
Study 12182264 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus skills-based safer sex training (I + B)
Number of subjects: 161
Study 12182264 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus skills-based safer sex training and risk-sensitization manipulation (I + M + B)
Number of subjects: 161
Study 10213211 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose paclitaxel (135 mg/m2, 24-h i.v. infusion)
Number of subjects: 146
Study 10213211 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose paclitaxel (250 mg/m2, 24-h i.v. infusion)
Number of subjects: 146
Study 10213211 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of paclitaxel concentrations from both treatment arms
Number of subjects: 146
Study 10213211 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel Css,avg
Number of subjects: 146
Study 10213211 — intervention group
Group type: EXPERIMENTAL
Intervention: Worst grade of leukopenia
Number of subjects: 146
Study 10213211 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of demographic and stratification variables
Number of subjects: 146
Study 10213211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower disease stage (stage IIIb)
Number of subjects: 146
Study 10213211 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 146
Study 10213211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower ECOG performance status (= 0)
Number of subjects: 146
Study 8547682 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection control measures implemented at Facility A (increased surveillance, handwashing reinforcement, isolation of symptomatic residents, and relief of symptomatic staff from duties).
Number of subjects: 0
Study 8547682 — intervention group
Group type: EXPERIMENTAL
Intervention: More stringent infection control measures implemented at Facility B (all measures from Facility A plus additional restrictions on staff movement, closure of affected units to new admissions, enteric precautions for ill residents, restriction of residents to their own units, and education about gastroenteritis).
Number of subjects: 0
Study 8547682 — intervention group
Group type: COMPARATOR
Intervention: Comparison of attack rates between Facility A and Facility B.
Number of subjects: 0
Study 2198297 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 14
Study 2198297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 655675 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term 5-FU administered after postoperative irradiations for gastric cancer
Number of subjects: 0
Study 655675 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole as adjuvant treatment for colon cancer
Number of subjects: 0
Study 655675 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in advanced colon cancer
Number of subjects: 0
Study 655675 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy for rectal cancer
Number of subjects: 0
Study 655675 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy as a preoperative irradiation sensitizer in rectal cancer
Number of subjects: 0
Study 31830976 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion proctectomy and IPAA without defunctioning ileostomy (experimental group)
Number of subjects: 194
Study 31830976 — intervention group
Group type: COMPARATOR
Intervention: Completion proctectomy and IPAA with defunctioning ileostomy (control group)
Number of subjects: 194
Study 31830976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies (with and without ileostomy)
Number of subjects: 194
Study 28222422 — intervention group
Group type: COMPARATOR
Intervention: Exercise-only control (E)
Number of subjects: 454
Study 28222422 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss (D)
Number of subjects: 454
Study 28222422 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss + exercise (D+E)
Number of subjects: 454
Study 25634107 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual biofeedback from the display monitor, in the form of symbolic feet as the subject took a step
Number of subjects: 30
Study 25634107 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory biofeedback associated display, using a metronome at 115% of the individual's preferred cadence
Number of subjects: 30
Study 25634107 — intervention group
Group type: COMPARATOR
Intervention: Partial body weight supported (PBWS) treadmill training
Number of subjects: 30
Study 25634107 — intervention group
Group type: COMPARATOR
Intervention: Control group (only PBWS treadmill training)
Number of subjects: 30
Study 23559124 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 µg
Number of subjects: 11
Study 23559124 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 800 µg
Number of subjects: 11
Study 23559124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 21184876 — intervention group
Group type: EXPERIMENTAL
Intervention: Water method
Number of subjects: 100
Study 21184876 — intervention group
Group type: COMPARATOR
Intervention: Air method
Number of subjects: 100
Study 19522395 — intervention group
Group type: EXPERIMENTAL
Intervention: Xiaoyusan plaster and Daoyin
Number of subjects: 63
Study 19522395 — intervention group
Group type: COMPARATOR
Intervention: Votalin Sustained Release Tablets
Number of subjects: 63
Study 18091987 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% C31G (SAVVY) gel
Number of subjects: 2142
Study 18091987 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 2142
Study 15570357 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2064
Study 15570357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2064
Study 11064611 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 11064611 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 40
Study 11064611 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 40
Study 8738073 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. meperidine 100 mg
Number of subjects: 48
Study 8738073 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. tramadol 100 mg
Number of subjects: 48
Study 8738073 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 48
Study 1493086 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glucagon from pancreatic extraction intramuscularly
Number of subjects: 10
Study 1493086 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg genetically engineered glucagon intramuscularly
Number of subjects: 10
Study 1493086 — intervention group
Group type: COMPARATOR
Intervention: 25 g glucose intravenously
Number of subjects: 10
Study 2859712 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole, 10 mg on rising
Number of subjects: 85
Study 2859712 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine, 60 mg on rising and in the evening
Number of subjects: 85
Study 30479519 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS) during Roller Massage (RM)
Number of subjects: 0
Study 30479519 — intervention group
Group type: COMPARATOR
Intervention: Rolling without TENS application (Control)
Number of subjects: 0
Study 28697860 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal nutritional management (MNM)
Number of subjects: 162
Study 28697860 — intervention group
Group type: COMPARATOR
Intervention: Traditional protocol
Number of subjects: 162
Study 26710337 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic warfarin dosing
Number of subjects: 200
Study 26710337 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacodynamic method (Control)
Number of subjects: 200
Study 22056474 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering medication
Number of subjects: 2263
Study 22056474 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle advice (weight reduction, healthy diet, physical activity, no-smoking)
Number of subjects: 2263
Study 21047696 — intervention group
Group type: EXPERIMENTAL
Intervention: New prognostic score developed from training dataset
Number of subjects: 687
Study 21047696 — intervention group
Group type: EXPERIMENTAL
Intervention: New prognostic score
Number of subjects: 687
Study 21047696 — intervention group
Group type: COMPARATOR
Intervention: BCLC and CLIP scores
Number of subjects: 687
Study 21047696 — intervention group
Group type: EXPERIMENTAL
Intervention: CLIP + PS
Number of subjects: 687
Study 18813411 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate 50 mg daily for 60 days
Number of subjects: 60
Study 18813411 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 60
Study 16730766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pastorex® latex agglutination test
Number of subjects: 484
Study 14690101 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural levobupivacaine 0.5% 15 mL
Number of subjects: 65
Study 14690101 — intervention group
Group type: COMPARATOR
Intervention: Epidural ropivacaine 0.75% 15 mL
Number of subjects: 65
Study 10733052 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (60/80 mg)
Number of subjects: 603
Study 10733052 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrifonate (40/50 mg)
Number of subjects: 603
Study 10733052 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study 8604962 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antihypertensive drug therapy
Number of subjects: 4367
Study 8604962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4367
Study 1356466 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 705
Study 1356466 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile saline
Number of subjects: 705
Study 2414783 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (25 micrograms)
Number of subjects: 8
Study 2414783 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (75 micrograms)
Number of subjects: 8
Study 2414783 — intervention group
Group type: COMPARATOR
Intervention: Control skin area
Number of subjects: 8
Study 30691013 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching sessions (n = 12 calls) with SMS prompting (n = 48 SMSs)
Number of subjects: 288
Study 30691013 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone coaching sessions (n = 12 calls) without SMS prompting
Number of subjects: 288
Study 30691013 — intervention group
Group type: COMPARATOR
Intervention: Single written PA recommendation (minimal intervention group)
Number of subjects: 288
Study 29280723 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy with adjustment of challenge-skill balance
Number of subjects: 56